Overview * Clene ( CLNN ) reports Q3 net loss of $8.8 mln, increased from $8.0 mln last year * Cash and cash equivalents total $7.9 mln, runway extended into Q2 2026 * Company plans NDA submission for CNM-Au8 in Q1 2026 under accelerated approval Outlook * Clene plans to submit NDA for ALS treatment in Q1 2026 * Company...

Overview * Oblong Q3 revenue grows 4% yr/yr, reaching $0.6 mln * Net loss widens to $2.3 mln, impacted by $1.5 mln TAO revaluation loss * Adjusted EBITDA loss narrows 26% yr/yr to $0.7 mln Outlook * Oblong highlights upcoming block-reward halving in December 2025 as a significant event * Company expects Bittensor network upgrades to enhance scalability and performance...

Overview * SINTX ( SINT ) Q3 revenue of $0.2 mln missed analyst expectations * Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln * Company strengthened liquidity with $4.3 mln raised through warrant exercises Outlook * SINTX ( SINT ) plans to launch the SINAPTIC wedge system in the near term * Company aims to expand clinical...

Overview * Cingulate ( CING ) Q3 net loss of $7.3 mln missed analyst expectations * R&D expenses rose 99.5% due to NDA submission costs for CTx-1301 * FDA accepted NDA for CTx-1301 with PDUFA date of May 2026 Outlook * Company anticipates needing $7 mln additional capital before May 2026 PDUFA date * Cingulate ( CING ) plans potential...